Ernexa Therapeutics宣布FDA新药临床试验前会议成功持续推动卵巢癌首个人体试验进展_老虎社区_美港股上老虎

Ernexa Therapeutics宣布FDA新药临床试验前会议成功持续推动卵巢癌首个人体试验进展

美股速递01-06

Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。

公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1182808693?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-06 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182808693","market":"us","top_or_hot":-1,"title":"Ernexa Therapeutics宣布FDA新药临床试验前会议成功 持续推动卵巢癌首个人体试验进展","media":"美股速递","content":"<p>Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。</p>\n<p>公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ernexa Therapeutics宣布FDA新药临床试验前会议成功 持续推动卵巢癌首个人体试验进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErnexa Therapeutics宣布FDA新药临床试验前会议成功 持续推动卵巢癌首个人体试验进展\n</h2>\n\n<h4 class=\"meta\">\n\n2026-01-06 21:15 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。\n公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1182808693","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182808693","pubTimestamp":1767705313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。\n公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","ERNA":"Eterna Therapeutics Inc."},"translate_title":"Ernexa Therapeutics announces the success of the FDA pre-clinical trial meeting for new drugs and continues to promote the progress of the first human trial of ovarian cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERNA":1},"content_text":"Ernexa Therapeutics近日宣布，其与美国食品药品监督管理局（FDA）举行的新药临床试验前（Pre-IND）会议取得圆满成功。此次会议为公司在卵巢癌领域开展首个人体试验扫清了关键监管障碍。\n公司表示，基于FDA的积极反馈，团队正加速推进相关准备工作，朝着启动首次人体临床试验的目标稳步迈进。这一进展标志着Ernexa Therapeutics在卵巢癌创新疗法开发道路上迈出了重要一步。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}